These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8453691)

  • 21. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
    J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.
    Nalda-Molina R; Valenzuela B; Ramon-Lopez A; Miguel-Lillo B; Soto-Matos A; Perez-Ruixo JJ
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):97-108. PubMed ID: 18941750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
    Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
    Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
    Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
    J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distribution of [14C]suramin in tissues of male rats following a single intravenous dose.
    McNally WP; DeHart PD; Lathia C; Whitfield LR
    Life Sci; 2000 Sep; 67(15):1847-57. PubMed ID: 11043607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
    Kobayashi K; Vokes EE; Vogelzang NJ; Janisch L; Soliven B; Ratain MJ
    J Clin Oncol; 1996 Sep; 14(9):2622-3. PubMed ID: 8823342
    [No Abstract]   [Full Text] [Related]  

  • 27. Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
    Zhou H; Choi L; Lau H; Bruntsch U; Vries EE; Eckhardt G; Oosterom AT; Verweij J; Schran H; Barbet N; Linnartz R; Capdeville R
    J Clin Pharmacol; 2000 Mar; 40(3):275-83. PubMed ID: 10709156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.
    Paxton JW; Hardy JR; Evans PC; Harvey VJ; Baguley BC
    Cancer Chemother Pharmacol; 1988; 22(3):235-40. PubMed ID: 3409457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.
    Hu L; Wientjes MG; Li J; Au JL
    AAPS J; 2010 Dec; 12(4):586-91. PubMed ID: 20625863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
    Piscitelli SC; Forrest A; Lush RM; Ryan N; Whitfield LR; Figg WD
    Pharmacotherapy; 1997; 17(3):431-7. PubMed ID: 9165547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
    Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial.
    Motzer RJ; Dmitrovsky E; Miller WH; Tong WP; Bajorin DF; Scher HI; Bost GJ
    Cancer; 1993 Dec; 72(11):3313-7. PubMed ID: 8242558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers.
    Kosarek CE; Hu X; Couto CG; Kisseberth WC; Green EM; Au JL; Wientjes MG
    J Vet Intern Med; 2006; 20(5):1172-7. PubMed ID: 17063712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer.
    Fujita K; Yoshino E; Kawara K; Maeda K; Kusuhara H; Sugiyama Y; Yokoyama T; Kaneta T; Ishida H; Sasaki Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):793-801. PubMed ID: 26297058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
    Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
    Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
    Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
    Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
    Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.